



Viva Biotech announced approximately US\$15 million in additional funding with ICD investment

Viva Biotech Holdings (1873.HK) announced that it will receive nearly US\$15 million in financing, transferring about 2.33% of its stake in Viva Biotech (Shanghai) Limited. The transaction values Viva Biotech (Shanghai) at approximately 4.6 billion RMB. This round of investment marks ICD's first direct investment project in China, reflecting its full recognition of Viva Biotech's unique position in the global innovative drug discovery industry. Additionally, ICD's involvement will provide significant strategic support for Viva's global business development and help to further enhance synergies.

Viva Biotech Secures Approximately US\$ 210 Million Funding

On November 20, 2023, Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US\$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light. Following this transaction, the Viva Biotech Holdings group obtained financing of nearly US\$150 million through the transfer of approximately 24.21% equity in its CRO business entity, Viva Biotech (Shanghai) Limited. Before, the publicly listed company at the group level had already secured approximately US\$ 60 million in convertible bond financing, which will be automatically converted into shares at the price of 2.0 HKD/share on the delivery date.

Dr. Cheney Mao, Chairman and CEO of Viva Biotech, stated that we are pleased to announce the completion of the equity investment and convertible bond arrangement with our strategic investors. This step is pivotal for our future strategic plans, fostering Viva's rejuvenation and sustainable growth, and leading to greater value and returns. At Viva Biotech, innovation remains our cornerstone, as we continuously improve our state-of-the-art technology platforms, fully leveraging the capabilities of our globally recognized drug research and development service platform, among other ventures. Looking ahead, Viva Biotech is committed to maintaining its unique approach to providing comprehensive, one-stop services in drug research, development, and production. Leveraging our extensive experience and unique position in pioneering First-in-class drug discovery, coupled with our comprehensive service offerings, we are dedicated to delivering specialized, customized, full-range services to the global biotech and pharmaceutical industries. This commitment is underpinned by the profound expertise of our highly skilled team of scientists.



维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
股票代码:1873



Issue 16
NEWSLETTER

 VIVA Company News

October – December 2023

Viva Biotech was honored with "the Influential Preclinical CRO Company of the Year" award

The fourth session China Biopharmaceutical Industry Chain Innovation and Transformation International Summit, along with the Awarding Ceremony of the fourth session China Biopharmaceutical Industry China Innovation Talents, was held in Hangzhou on December 15th. Viva Biotech was honored with "the Influential Preclinical CRO Company of the Year" award at the 2023 Innovation Billboard.

This reward is a testament to Viva Biotech's innovative capabilities, service excellence, and influence in the industry. Innovation remains at the core of Viva Biotech's ethos. To date, Viva Biotech's CRO business line encompasses numerous core technology platforms. These include the molecular glue/PROTAC platform, Protein production and structural research, Cryo-EM technology platform, membrane protein research, drug screening technology, Bioassay deck, Computer-aided drug design(CADD), AI-driven drug design (AIDD), medicinal chemistry, therapeutic antibody discovery. Viva's approach synergizes biology and chemistry to deliver value to the global clientele. Furthermore, Viva Biotech is actively developing the V-DEL technology platform and advanced antibody discovery platform, marking another step forward in Viva's commitment to biopharmaceutical innovation.

In the future, Viva Biotech will continue to uphold its principles of excellence, innovation, and client achievement, consistently strengthening its technological barriers. This award inspires us to keep moving forward, striving to advance medical research and contribute more wisdom and strength to the development of the biopharmaceutical industry.

Viva Biotech awarded the Best Partner of 2023 Shanghai Makers Carnival

On 24th November, The 2023 Shanghai Makers Competition was successfully held in Jianan District. Viva Biotech was honored with "the Best Partner of 2023 Shanghai Makers Carnival" award. The Viva BioInnovator (VBI), as the core department of Viva Biotech's investment and incubation business, is committed to being a collaborative platform for Innovative Biotech companies from around the world. By leveraging Viva Biotech's rich experience and technical advantages in novel drug R&D, Viva BioInnovator is dedicated to providing a series of professional post-investment management solutions based on the various needs of new drug R&D and company growth stages to continuously optimize the biopharmaceutical innovation ecosystem. As of June 30, 2023, Viva BioInnovator has invested in and incubated 92 biotech start-ups in total, covering the fields of oncology, immune diseases, cardiovascular diseases, ophthalmic diseases, metabolic diseases, central nervous system diseases, infectious diseases, and other indications. During the competition, we shared our innovation experience and explore cooperation opportunities. Through exchanges with industrial partners, managing partners, and investment partners, we jointly ignited the innovation engine, helping to launch innovative projects and set them on a course for success.

Research & Development Progress

The Phase II clinical trial application of VVN461 for the treatment of postoperative inflammation in cataract was approved by the U.S. FDA

VivaVision, invested and incubated by Viva BioInnovator (VBI), is an innovative ophthalmic drug company. Recently they announced that the FDA approved the Phase II clinical trial application (IND) of VVN461, the company's self-developed drug, for the treatment of postoperative inflammation after cataract.



VVN461 is a potent JAK1 immunomodulator independently developed by VivaVision, and there is increasing evidence showing that the JAK-STAT signaling pathway is essential for inflammation and immune response. VVN461 can inhibit multiple inflammatory cytokine pathways with high activity to treat postoperative inflammation of cataracts. The results of human pharmacokinetic studies showed that VVN461 ophthalmic solution had low exposure in plasma, indicating that VVN461 ophthalmic solution had a high safety profile due to low systemic toxicity while exerting local anti-inflammatory effects.

ArthroSi to Present Positive Phase 2 Data for its Novel Selective Urat1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023

ArthroSi Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biotechnology company developing treatments for gout that dissolve uric acid crystals and prevent joint damage. Recently they announced new clinical data from its phase 2 AR882-203 study in patients with tophaceous gout. The late-breaking data has been presented as an oral presentation at the American College of Rheumatology (ACR) Convergence 2023 meeting, held in San Diego, CA on November 10-15, 2023.



In the late-breaking oral presentation, Dr. Robert Keenan MD, MPH, MBA, Chief Medical Officer of ArthroSi, has unveiled compelling new clinical findings from the phase 2 trial. The data showcases the strong efficacy of AR882, demonstrating significant reduction of tophi, crystal burden, flare rates, in addition to lowering sUA among patients suffering from tophaceous gout.



Business Progress

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

absci.

Absci Corporation (Nasdaq: ABSI), invested by Viva BioInnovator (VBI), is a leader in generative AI antibody discovery. They announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.

Absci will contribute its pioneering generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales.

Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies

PHENOMIC.AI
PHENOTYPIC BIOLOGICS DISCOVERY

Phenomic AI Inc. ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), is a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform. They have entered into a strategic research collaboration with Astellas Pharma Inc., "Astellas" through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas). For this collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of the tumor stroma identified with Phenomic's scTx platform, to enhance cell therapy approaches for the treatment of solid tumors.

Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies

PHENOMIC.AI
PHENOTYPIC BIOLOGICS DISCOVERY

Phenomic AI ("Phenomic") announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers.



Investment Progress

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care



AmacaThera, invested and incubated by Viva BioInnovator (VBI), is a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform. They announced the closing of a CAD\$4.0 million financing round, with a new lead investor, supported by existing investors; BDC Capital's Women in Technology Venture Fund, Inveready, Lumira Ventures, StandUp Ventures, and MaRS IAF. The proceeds will be used to accelerate the clinical development of the lead clinical candidate, AMT-143, and also to advance multiple pipeline programs targeting the local, injectable, sustained release market.

Deka Biosciences Closes USD \$20 Million Series B2 Financing Led by MPM BioImpact



Maryland-based biotech company Deka Biosciences ("Deka") announced that it has successfully closed a USD \$20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm. The proceeds of the financing will support the advancement of Deka's pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their investigational new drug (IND) application to evaluate DK210 (EGFR). Additionally, Detlev Biniszkiwicz, Ph.D. of MPM-BioImpact, will join the Deka board.

VIVA About Viva Biotech

Listing Date

2019.05.09

Price (2024.01.24)

HKD 0.72

52 WK Range

HKD 0.66-2.19

Market Cap (2024.01.24)

HKD 1.556 B

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage structure-based drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of December 31, 2022, Viva Biotech has provided drug R&D and production services to 2,076 biotech and pharmaceutical clients around the world. We have invested and incubated 91 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva's platform.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com

For further information, please contact: Tel: 852-3150 6788

Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com